Pharma C Investments - Issue of Equity
30/06/2022 10:29
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220630:nRSd8232Qa&default-theme=true
RNS Number : 8232Q Pharma C Investments PLC 30 June 2022
30 June 2022
Pharma C Investments Plc
("Pharma C" or the "Company")
Issue of Equity
Pharma C Investments (AQSE: PCIL), an early-stage investor and venture builder
in the medical cannabis industry, is pleased to announce that is has raised
£200,000 before expenses by way of a subscription for 80 million new ordinary
shares at a price of 0.25p per share ("the Subscription"). The proceeds of the
Subscription will be used to provide the Company with additional working
capital.
Application will be made for them to be admitted to trading on AQSE, which is
expected to be on or around 8 July 2022.
The new ordinary shares will rank pari passu with the existing ordinary shares
of the Company. Following the issue of the new ordinary shares, the
Company's issued share capital will comprise 349,857,144 ordinary shares of
0.1p (including the 80 million new ordinary shares).
The above figure of 349,857,144 should be used by shareholders in the Company
as the denominator for the calculations by which they will determine if they
are required to notify their interest in, or a change to their interest in,
the share capital of the Company under the Financial Conduct Authority's
Disclosure Guidance and Transparency Rules.
The Directors of Pharma C Investments plc take responsibility for this
announcement.
This announcement contains information which, prior to its disclosure, was
inside information as stipulated under Regulation 11 of the Market Abuse
(Amendment) (EU Exit) Regulations 2019/310 (as amended).
- Ends -
Gavin Sathianathan, Investment Strategy Director, Pharma C Investments
gavin@pharmacinvestments.com
David Coffman / Lucy Bowden
Novum Securities
(AQSE Corporate Adviser)
Tel: +44 207 399 9429
About Pharma C
Pharma C Investments is an investment vehicle targeting the legal medicinal
cannabis industry globally. The Company is seeking to identify breakout
companies within the legal markets with a particular focus on the UK, EU and
Israel and will provide capital, strategic insights and operational support.
Pharma C is run by cannabis entrepreneurs who understand the unique challenges
of the legal cannabis industry and thus can provide invaluable support and
expertise for growing companies.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NEXZZGFVLGNGZZG